Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

NorthSea Therapeutics announces late breaking oral presentation of Phase 2 topline data of Orziloben in Intestinal Failure-Associated Liver Disease at AASLD The Liver Meeting® 2026 onsemi to acquire Ferric, establishing leadership in power delivery for next-generation AI processors PlanetiQ expands GNSS-RO coverage with second satellite launch this month Promaxo lands $100M credit facility and Series C for MRI prostate platform Long Wall announces $75 million award from the Missile Defense Agency for Cyclops low-cost interceptor Resolve Therapeutics presents preclinical data on NET degradation and nuclease therapy in acute ischemic stroke at the World Stroke Conference
Back To News
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
May 11, 2021

Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.

 

Cookie Policy Website powered by 100% renewable energy Privacy Policy